Neutrexin

   
Google
 
Web NewDrugInformation.com

Neutrexin


Drug - Neutrexin
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Trimetrexate Glucuronate
Multiple ingredients are in alphabetical order.

Strength - EQ 200MG BASE/VIAL
The potency of the active ingredient(s), Trimetrexate Glucuronate. May repeat for multiple part products.

Applicant - MEDIMMUNE ONCOLOGY
The firm name holding legal responsibility for Neutrexin. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020326
The FDA assigned number to Neutrexin. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Neutrexin. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jul 31, 1998
The date Neutrexin was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Neutrexin. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Neutrexin is in. Format is RX, OTC, DISCN.

Applicant Full Name - Medimmune Oncology Inc
The full name of the firm holding legal responsibility for the new application of Neutrexin.

Neutrexin